Open AccessEffectiveness of Biological Agents in the Treatment of Pediatric Patients with Crohn’s Disease and Anal Fistulae
Author(s) -
Noriko Arai,
Toshifumi Kudo,
Kazuhide Tokita,
Reiko Kyodo,
Masamichi Sato,
Eri Miyata,
Kenji Hosoi,
Tamaki Ikuse,
Keisuke Jimbo,
Yoshikazu Ohtsuka,
Toshiaki Shimizu
Publication year - 2021
Publication title -
digestion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.882
H-Index - 75
eISSN - 1421-9867
pISSN - 0012-2823
DOI - 10.1159/000512900
Subject(s) - medicine , crohn's disease , fistula , gastroenterology , surgery , colostomy , anal fistula , disease
Anal fistulae have a significant impact on the quality of life of patients with Crohn’s disease (CD). In this cross-sectional study, we aimed to determine whether biological agents were effective in treating anal fistulae in patients with CD. Methods: Fifty-three patients diagnosed with CD were retrospectively enrolled. Their data regarding symptoms, treatments, and disease progression from January 2007 to December 2016 were reviewed from the medical records. Fifteen (28%) patients with CD were complicated by anal fistulae. Results: The male-to-female ratio was 13:2, and the mean age at onset was 11 years and 6 months. Among the 15 patients, 14 (93%) had anal fistulae as an initial symptom. Almost all patients were treated by providing elemental diet, 5-aminosalicylic acid, and steroids as induction therapy. Biological agents were used in 8 patients (53.3%), and fistula closure was confirmed in all of them. Among the 7 patients not treated with biological agents, 1 (14.3%) had a recurrent anal fistula, while another had incomplete fistula closure. Regarding surgical management, 2 patients were treated using the seton method, and no patients required a colostomy. Conclusion: Treatment with biological agents is highly effective concerning the closure of anal fistulae in patients with CD, and reducing pain may improve their quality of life.